Procarta is pleased to announce that Dr. Kostas Hatzixanthis has joined the company as Director of Research with a mandate to prepare for preclinical trials and project manage EU collaborations. In particular the Clostridium difficile programme which is being supported by a range of grant funding, academic and commercial collaborators. Previously Dr. Hatzixanthis had a role with Phico Therapeutics managing their clinical trial programmes. Dr Hatzixanthis has significant industrial bioprocessing experience for the manufacture of novel drug therapeutics.
Executive Chairman Dr. David Knowles commented that, "Kostas's appointment represents a step forward for the company as we continue to develop our pipeline and bring these products closer to the market."